Ž . Objectives: We tested the hypothesis that endothelin-1 ET-1 aggravates ischaemiarreperfusion injury by stimulating cellular Ž . L-arginine depletion, which would result in reduced synthesis of nitric oxide NO and withdrawal of cardioprotection. Methods: Five Ž . groups of rat hearts n s 5 each were perfused at 9 mlrmin per g for 45 min, subjected to 15 min total global ischaemia and reperfused Ž . for 30 min; they received, from 5 min pre-ischaemia to end of reperfusion, either vehicle, L-arginine 1 mmolrl , the NO donor Ž . . LDH into coronary effluent were measured. Results: Systolic, diastolic, and coronary reperfusion function were consistently improved Ž . by L-arginine, SNAP, or PD 142893, but worsened by L-NNA P -0.05 in each case . L-arginine release was transiently increased up to Ž . Ž . 25-fold on reperfusion vehicle ; release was reduced by SNAP mean: 68% and entirely prevented by PD 142893. Despite the increased Ž . outflow of L-arginine, formation of cyclic GMP was not reduced, but enhanced in reperfusion 11-fold; vehicle , and SNAP further augmented this release, but L-NNA had no significant effect. Release of LDH was decreased by L-arginine, SNAP, and PD 142893 in reperfusion. Finally, release of ET-1 was inhibited by NO in normoxia as well as throughout reperfusion as evident from the stimulatory effect of L-NNA. Conclusion: In ischaemia, ET-1 causes cell necrosis and L-arginine outflow without compromising NO synthesis in this model. q 1997 Elsevier Science B.V.
Introduction
The endothelium produces several vasodilator and vasoconstrictor substances that regulate blood vessel tone and w x exert a number of other cardiovascular effects 1 . Two important factors produced by the endothelium are enw x dothelium-derived relaxing factor 2 , generally agreed to w x Ž . w x be nitric oxide 3,4 , and endothelin-1 ET-1 5 . Recent studies focused on the role of the endothelium in cardiac ischaemia-reperfusion injury which is associated with considerable damage to myocytes and coronary arteries. A prominent feature of post-ischaemic endothelial cell dysfunction is a decrease in endothelium-dependent vasodilaw x tion in isolated blood vessels and intact vascular beds 6,7 , and studies into its mechanisms have implicated the NOcyclic GMP pathway. Basal release of NO from rat hearts w x appeared diminished after ischaemia and reperfusion 8, 9 , and the pathophysiological consequences due to impaired NO release were mitigated or abolished by providing w x w x exogenous NO donors 8,10 , authentic NO 11 , or the NO w x precursor L-arginine 12-14 , suggesting that cellular Larginine depletion may play a role in these defects. In other studies, however, inhibitors of NO synthase were found to exert protective, rather than injurious effects w x 15,16 , possibly via indirect mechanisms.
There is now substantial evidence that the formation of w x ET-1 is enhanced during myocardial ischaemia 17 and that pretreatment of hearts with receptor antagonists reTime for primary review 22 days. 21, 22 . These discrepancies may in part relate to the balance, in a given experimental setting, of pro-ischaemic actions of ET-1, which include coronary constriction and impairment of systolic and diastolic function, and anti-ischaemic effects such as increased release of vasodilator prostanoids and endothelium-derived NO. In addition, reciprocal interactions between the ET and LargininerNO systems in conjunction with increased cytosolic free Ca 2q concentrations observed in ischaemic w x hearts 23 might be of importance. Data from cultured endothelial cells suggest that the formation of ET-1 and w x NO is increased in this condition 24,25 and that feed-back inhibition of ET-1 formation by NO may also play a role. However, the importance of these mechanisms in intact hearts subjected to ischaemia and reperfusion is not known.
Based on this evidence we hypothesized that increased release of ET-1 might promote ischaemiarreperfusion injury resulting in myocardial and endothelial cell death which would secondarily lead to depletion of cellular L-arginine, withdrawal of cardioprotection due to reduced synthesis of NO, and further ET-1 release. Therefore, the Ž . purposes of this study were 1 to determine the role of L-argininerNO and ET-1 after myocardial ischaemia with Ž . reperfusion and 2 to relate the recovery of coronary and myocardial function after reperfusion to alterations in release of L-arginine and cyclic GMP as well as lactate Ž . dehydrogenase LDH , an established marker of cell viability.
Methods

Materials
L-arginine and L-NNA were purchased from Sigma Ž . Ž Vienna, Austria ; SNAP was from Tocris Cookson Bris-. tol, UK ; 2,2-diethyl-1-nitrosooxyhydrazine = 1 Na Ž . Ž DEArNO was from Research Biochemicals Natick, MA, . Ž USA ; PD 142893 Ac-D-diphenylalanine-Leu-Asp-Ile-Ile-. Trp = 2 Na was the kind gift of Dr. Annette Doherty from Ž Parke-Davis Pharmaceutical Research Ann Arbor, MI, . USA . All other chemicals were of standard purity.
Heart perfusion
Ž
. Sprague-Dawley rats 260-320 g were anaesthetized with diethyl ether, the hearts removed, arrested in cold solution and immediately mounted in a Langendorff perfusion system. Heart beats resumed within 85 s of thoraco-Ž . tomy within 2.5-3 min after start of anaesthesia . Hearts were perfused in the non-recirculating mode at a flow rate of 9 mlrmin per g heart wet weight with a modified Ž Krebs-Henseleit bicarbonate buffer composition in mmolrl: NaCl 118, NaHCO 25, KH PO 1.2, KCl 4.8, 3 2 4
. MgSO 1.2, CaCl 1.25, glucose 11 using the ISO- 4 2 Ž HEART perfusion system Hugo Sachs Elektronik, . w x March-Hugstetten, Germany as described previously 26 . Cardiac parameters were monitored continuously and in-Ž . cluded heart rate, coronary perfusion pressure CPP , left Ž ventricular developed pressure LVDevP; difference between left ventricular peak systolic pressure and end-di-. astolic pressure , and left ventricular end-diastolic pressure Ž . LVEDP . All animals received care in accordance with the ''Austrian Law on Experimentation with Laboratory Ž . Animals'' last amendment, 1989 which is based on the principles of laboratory animal care as adopted by the American Heart Association and the Declaration of Helsinki.
Experimental protocol
Ž . Hearts were perfused for 45 min baseline , followed by 15 min of global ischaemia, and finally reperfused for 30 min at normal flow. The hearts were thermostated at 37 Ž . ischaemia: 358C . Some hearts were perfused for 90 min under normoxic conditions. The following drugs were added to the perfusion medium 5 min before start of Ž . ischaemia to the end of reperfusion final concentrations :
Ž . L-arginine 1 mmolrl , the physiological precursor for the formation of NO; S-nitroso-N-acetyl-DL-penicillamine Ž . 
Measurement of L-arginine and LDH
The HPLC method used for quantitative analysis of L-arginine was adapted from procedures described previw x Ž . ously 28 . Coronary effluent samples 0.1 ml were treated Ž . with acetonitrile 0.1 ml at ambient temperature for 10 min, followed by centrifugation at 12 000 = g for 3 min. The supernatant was dried and the resulting sediment Ž dissolved in 20 ml Na-bicarbonate buffer 50 mmolrl, pH . 8.1 . This solution was combined with 40 ml of the w Ž . derivatization solution 4 mmolrl 4-dimethylaminox azobenzenesulfonyl chloride in acetonitrile and heated for 12 min at 708C in a water bath. After derivatization, Ž samples were diluted with citrate buffer 10 mmolrl, pH 4.6, containing 30% acetonitrile and 4% dimethyl for-. Ž mamide to a final volume of 0.5 ml dilution of effluent . Ž . s 1 : 5 . Aliquots 10 ml of the diluted samples were Ž injected onto an Ultrasphere XL-ODS 3 mm 4.6 = 70 . mm column equipped with an integrated guard column Ž . Beckman; Vienna, Austria . Separation was achieved at ambient temperature with a binary gradient at a flow rate Ž of 1.2 mlrmin. Solvent A was Na-citrate 13 mmolrl, pH . 6.4 containing 4% dimethyl formamide; solvent B was a mixture of 30% solvent A and 70% acetonitrile containing 4% dimethyl formamide. The gradient was 30% B to 56% B in 10.6 min, 56% B to 86% B in 1.7 min, then kept at 86% B for 1.38 min, 86% B to 100% B in 0.5 min, kept at 100% B for 3 min, returned to 30% B in 0.5 min and equilibrated for 2 min at starting conditions. The cycle time from injection to injection was 22 min. The detector wavelength was 436 nm. Calibration of the method with authentic L-arginine yielded linear responses of peak areas vs concentration in the range of 1 to 20 pmolrinjection. The effluent samples contained ; 1-10 pmol L-arginine per injection. w x LDH was measured as described previously 25 .
Determination of ET-1 and cyclic GMP
ET-1 was concentrated by solid-phase extraction followed by quantitative radioimmunoassay as described prew x viously 26 . Briefly, coronary effluents were chromato-TM Ž graphed on C2 Ethyl Spe-ed cartridges Inovec; Vienna, . Ž . Austria , and ET-1 was eluted with acetonitrile 70% , the eluate freeze-dried, and ET-1 contained in the sediment was dissolved in buffer and determined by RIA using an Ž . ET-1-specific antibody Peninsula; Belmont, CA, USA . Cyclic GMP in coronary effluents was determined directly by radioimmunoassay essentially as described previously w x 29 . Standard curves were established in Krebs-Henseleit Ž . buffer pH 8.0 containing 1 mmolrl 3-isobutyl-1-methylxanthine to inhibit cyclic nucleotide-dependent phosphodiesterases.
Statistical analysis
Group data are presented as arithmetic mean values " SEM. Hemodynamic parameters were evaluated by two-Ž . way analysis of variance ANOVA for repeated measure-Ž ments to account for different treatments control, is-. Ž . chaemia, reperfusion and additions vehicle and drugs . When a significant overall effect was detected, the Scheffé test was used to compare single mean values. A probability of less than 5% was considered significant. P values less than 0.01 were not indicated separately.
Results
Control perfusions in normoxic hearts
First, control perfusions in normoxic perfused hearts not subjected to ischaemia were done in hearts not treated Ž . vehicle or treated with drugs. For vehicle, heart rate was 311 " 6 beatsrmin, LVDevP was 90 " 2 mm Hg, and CPP was 54 " 2 mm Hg; LVEDP was set at 0 mm Hg at Ž . the end of equilibration 45 min . All parameters were stable throughout the duration of experiment. The NO Ž . synthase inhibitor L-NNA 200 mmolrl had no effect on Ž . heart rate 300 " 10 beatsrmin , but reduced LVDevP to Ž . 
Effect on ischaemic and reperfusion function
As expected, no-flow ischaemia resulted in cessation of Ž . left ventricular contractile activity Fig. 1A , an increase in Fig. 1B and a collapse of CPP Fig. 1C ; heart beat slowly ceased. After 30 min of reperfusion, heart rate Ž . returned to baseline s pre-ischaemic level, but LVDevP remained depressed to 74%, LVEDP was elevated to 24 " 1 Ž mm Hg, and CPP was increased 2.1-fold vehicle; each . P -0.05 vs. baseline . In the presence of L-arginine or Ž . SNAP 200 mmolrl , recovery of reperfusion function was considerably improved, so that parameters approached Ž baseline values LVDevP: 90% and 96% of baseline; LVEDP: 4 " 2 and 1 " 1 mm Hg; CPP: 1.2-fold and . Ž . 1.1-fold of baseline, respectively P ) 0.05 vs. baseline . NO synthase inhibition by L-NNA had opposite effects: LVEDP was elevated to 34 " 4 mm Hg, and CPP was Ž . increased 2.5-fold; LVDevP was unchanged 57% . Addi-Ž . tion of the ET receptor antagonist PD 142893 200 nmolrl to the perfusion medium consistently improved cardiac and vascular function to a similar extent as SNAP. A statistical comparison between effects of test drugs and effects of vehicle during reperfusion was also done and is indicated in Fig. 1 .
Ž .
Ž . Fig. 2 . Concentration of L-arginine A and cyclic GMP B in coronary Ž effluent during reperfusion. Sampling was performed at baseline marked . with ''B'' at abscissa; i.e. 45 min post mounting of heart , and 5, 10, 20 and 300 s after initiation of reperfusion. Because of total no-flow Ž . ischaemia 45-60 min post mounting , no samples were obtained during the ischaemic period. Drugs were added to perfusion fluid 5 min before onset of ischaemia to the end of reperfusion. For concentration of drugs, see Fig. 1 . Results are means "SEM, ns 5. ) P -0.05 vs. vehicle. Fig. 3 . LDH concentration in coronary effluent during reperfusion. Sampling was performed as described in Fig. 2 and concentrations of drugs are given in Fig. 1 . Drugs were added to perfusion fluid 5 min before onset of ischaemia to the end of reperfusion. Results are means "SEM, ns 3. ) P -0.05 vs. vehicle.
Effect on L-arginine and cyclic GMP release
The concentration of endogenous L-arginine in coro-Ž nary effluent was 0.06 " 0.01 mmolrl at baseline To complement these measurements, the effector of Ž . NO, cyclic GMP, was also determined Fig. 2B . After infusion of vehicle, the concentration of cyclic GMP was elevated 11.1-fold in the first effluent sample collected Ž . after initiation of reperfusion P -0.05 vs. baseline ; baseline level was reached again after 5 min. As expected, Ž cyclic GMP was greatly increased by SNAP 52-fold vs.
. baseline . Neither PD 142893 nor L-NNA affected cyclic Ž . GMP in reperfusion P ) 0.05 vs. vehicle . Cyclic GMP levels were never lower than baseline throughout reperfusion.
Effect on LDH release
The LDH concentration in coronary effluent increased 9-fold within 5 s of reperfusion as compared to baseline Ž and declined to baseline level within 5 min Fig. 3 , . vehicle . The LDH concentration was decreased after infu-Ž . Ž . Ž sion of L-arginine 50-80% or SNAP 60-90% P -. Ž . 0.05 in each case ; L-NNA had no effect P ) 0.05 . Antagonism of ET receptors with PD 142893 reduced LDH release to the same level as observed with SNAP. LDH release was indistinguishable from baseline between Ž . 5 and 30 min of reperfusion data not shown . 
Effect of the L-argininer NO pathway on ET-1 secretion
In normoxic hearts, basal ET-1 release was constant Ž . 0.028 " 0.002 pgrml effluent; Fig. 4A . Addition of L-NNA to the perfusate increased the ET-1 concentration Ž within 30 min to 0.098 " 0.011 pgrml 3.5-fold; P -. 0.05 . As expected, ET-1 secretion was increased several Ž . Ž . fold after ischaemia Fig. 4B P -0 
Discussion
The present study tested the hypothesis that ET-1 released in ischaemiarreperfusion is associated with a loss of cellular L-arginine, reduced synthesis of NO, and withdrawal of cardioprotection by NOrcyclic GMP. We found, Ž . during reperfusion following ischaemia, 1 a protective effect of L-arginine, SNAP, and the ET receptor antagonist, and a deleterious effect of NO synthase inhibition on haemodynamic function, L-arginine release, and LDH re-Ž . Ž lease, and 2 that the synthesis of NO measured as cyclic . GMP was never lower than during normoxic perfusion despite augmented efflux of L-arginine from the heart. These results indicate for the first time that ET-1 damages myocytes and endothelial cells in the setting of ischaemiarreperfusion, which results in cell necrosis, Larginine outflow, and impaired reperfusion function but not in reduced formation of NO.
Neither PD 142893 nor SNAP had any effect on functional parameters under normoxic conditions, indicating that ET-1 production is substantially down-regulated by NO and that ET-1 exerts no measurable deleterious effects in normoxic-perfused hearts. In view of the protective Ž . effects of PD 142893 in ischaemia see below , the specificity of action of PD 142893 is of particular importance. In support, no non-specific vasodilator effect was ever observed with PD 142893 in normoxic perfusions, rather CPP was indistinguishable from vehicle values in all measurements throughout the protocol. Furthermore, PD 142893 completely blocked the vasoconstrictor effect of a test concentration of exogenous ET-1. Together, these data indicate that non-specific actions of the ET receptor antagonist can be excluded.
After ischaemia, impairment of vascular relaxation was evident from a doubling of CPP after 30 min of reperfusion. The additional reduction of vasodilator tone observed in the presence of L-NNA, as well as the substantial protective effect of L-arginine and SNAP, clearly indicated a lack of NO or NO activity in reperfusion vascular dysfunction. Endogenous ET-1 is likely to be an important factor in this impaired vascular relaxation because the post-ischaemic increase in CPP observed with vehicle was Ž effectively antagonized by the ET receptor antagonist Fig. . 1C . Besides these coronary effects, the antagonist also improved myocardial function as evident from a higher recovery of post-ischaemic LVDevP and a better post-Ž . ischaemic diastolic relaxation lower LVEDP . Because these effects were matched by a greatly reduced release of LDH after reperfusion, these data indicate that endogenous ET-1, in amounts generated by the ischaemic insult, plays a causal role in reperfusion injury in this model. A similar vascular protective effect was observed in the isolated w x w x rabbit heart 31 and in hearts of anaesthetized pigs 19 .
Examining the cellular mechanism of action of ET-1 was beyond the scope of our present objectives. With respect to myocyte function, it may involve an increase in
. w x intracellular Ca concentration Ca overload 32 , depletion of energy stores due to the positive inotropic effect w x 2q of ET-1 33 , or increased Ca sensitivity of myofibrils w x 34 . Despite suggestions that L-arginine deficiency may account for reduced NO synthesis and impaired vasorelaxw x ation 8,13,35 , so far L-arginine levels have apparently not been determined during post-ischaemic reperfusion. The Ž . present HPLC measurements Fig. 2A show clearly that L-arginine release into coronary effluent is increased some 25-fold above pre-ischaemic level after restoration of coronary flow, which amounted to a total L-arginine efflux of Ž . ;3 nmol within 5 min of reperfusion vehicle . Judgment of the significance of this efflux is hampered by the ignorance of its cellular origin. Clearly, the amount released is a substantial fraction of the endothelial cell Ž content ; 5-10 nmol based on published endothelial cell w x. dimensions and cytosolic L-arginine concentrations 36 , but would not represent a significant fraction of total cardiac L-arginine. The question was resolved by determining the time-course of cardiac cyclic GMP release into the same coronary effluents in which L-arginine was determined. They clearly showed an increased, rather than decreased level, indicating that the L-arginine release occurring at the same time does not result in reduced NO synthesis. This may be due to relatively high cellular w x L-arginine levels 36 being well above the concentration required for substrate saturation of NO synthases, which w x exhibit K values in the low micromolar range 37,38 . m The cyclic GMP recovered in reperfusion may have accumulated during preceding low-flow ischaemia and been washed out during reperfusion, because a model of low-Ž . flow ischaemia 0.2 mlrmin showed that the cyclic GMP appeared during the ischaemic phase rather than during Ž . reperfusion unpublished observations .
The lack of effect of L-NNA on cyclic GMP release was somewhat surprising and is presently being investigated. A preliminary explanation is that the steps leading to activation of guanylyl cyclase by NO are more complex than currently known, possibly involving storage forms of NO.
In cultured cells, NO attenuates the synthesis of ET-1 w x 39 , but since NO formation may be impaired in is-Ž . chaemia-reperfusion see Introduction , we expected the formation of ET-1 to be enhanced. Under normoxic conditions, ET-1 release into coronary effluent was tonically inhibited by NO as shown by the several-fold increase in Ž . ET-1 release in the presence of L-NNA Fig. 4A . Interest-Ž . ingly, even after ischaemia Fig. 4B , ET-1 formation was still subject to modulation by NO, as evident from its inhibition by donor-derived NO and the higher rate of ET-1 secretion in the presence of L-NNA. These novel observations indicate that the negative feed-back inhibition of ET-1 formation by NO remains functional, yet insufficient after ischaemia as evident from the suppression of all Ž deleterious effects by the ET receptor antagonist Figs. . 1-3 . Examining the mechanism of this counter-regulation was not intended here; it might result from stimulation of w x endothelial NO synthase 24 induced by a rise in cytosolic Ca 2q during ischaemia. Thus, our results suggest that the negative feed-back component of ET-1 formation remains operational in ischaemia, but is overridden by the inw x creased net release and action of ET-1 17 .
Conclusion
Our results indicate that under normoxic conditions, basal NO release results in tonic inhibition of ET-1 production, while the ischaemic insult triggers the synthesis and release of ET-1 which leads to receptor-mediated cell necrosis with concomitant LDH and L-arginine efflux. However, the latter does not cause reduced NO synthesis and does not appear to account for impairment of reperfusion coronary function in this buffer-perfused rat heart model.
